Saturday, October 31, 2026

Plastic Surgery in North Korea? It’s Real — and Strictly Controlled

North Korean women increasingly seek cosmetic surgery, leading to new regulations aimed at curbing illegal procedures and enhancing beauty standards.

Meta’s Muse Spark: The Next-Gen AI Model Outperforming Google and OpenAI

Meta launches Muse Spark, a next-gen AI model showcasing speed, efficiency, and superior reasoning capabilities across various domains.

Cristiano Ronaldo’s Retirement: What Will His Legacy Look Like After 25 Years in Football?

Cristiano Ronaldo announced he may retire after the upcoming season, calling it potentially the end of his football career.

Health

Unlock Your Health: Discover the New AI-Powered BioAge and Health Coach Services from DaNaA Data

Daewoo Group's AI health data firm, DaNaA Data, launched a service analyzing biological age, disease risk, and health check results.

How the New Medical School in Namwon Can Transform Regional Healthcare: Insights from Lawmaker Park Ji-won

Defining school locations alone won't solve local healthcare issues; deeper strategies are needed for effective solutions.

Ardens Lifescience Triumphs: How a Korean Startup Won 175,000 USD at MedTech Innovator APAC 2026

Adenz Life Sciences wins a global medical device competition, earning a prize of 175,000 USD.

Unlocking the Future of Healthcare: Daewoong’s AI-Powered Smart Hospital at AI EXPO MARS 2026

Daewoong Pharmaceutical introduces an AI-based smart hospital model for monitoring, diagnosis, testing, and rehabilitation.

10 Years of Excellence: Seoul’s APLAR Center Hosts International Rheumatology Training for Young Specialists

Seoul St. Mary's Hospital's Rheumatology Center held an international training program for foreign experts on October 27 and 26.
Latest

Onconic Therapeutics Unveils Promising New Drug Candidate Ahead of ObesityWeek 2026

Onconic Therapeutics announced its new drug candidate's first research results will be presented at ObesityWeek 2026 in Washington D.C.

SOT106: The Breakthrough ADC for Osteosarcoma and Soft Tissue Sarcoma Secures FDA Fast Track Status

LigaChem Biosciences' ADC platform SOT106 gains rare disease and fast track designations in the U.S., accelerating clinical entry for sarcomas.

Qurient Expands Dual Payload ADC Technology: What This Means for Cancer Treatment in 2026

Qurient expands its platform for Dual Payload antibody-drug conjugate technology, combining two types of anticancer agents in one antibody.

Samsung Biologics Redefines Biopharmaceuticals: 3.5-Month Development Time Reduction Revealed at BPI 2026

Samsung Biologics reveals process innovations that cut biopharmaceutical development time by 3.5 months and double cell culture productivity.

LigasChem Bio Unveils Preclinical Data on Multiple Myeloma ADC, Plans U.S. Clinical Trial Application This Year

LigasChem Bio reported that its next-generation BCMA-targeted ADC LCB43 showed strong antitumor activity and favorable tolerability in preclinical studies and plans to file for a U.S. clinical trial this year.

After 19-Year Push, HLB Wins First FDA Drug Approval With More Cancer Programs Ahead

HLB has secured its first U.S. Food and Drug Administration-approved drug after 19 years of development efforts, with follow-up programs in liver cancer, corneal disease and CAR-T therapies underway.

“Doctors Take Patients by the Hand to the Next Exam Room”: The Cancer Center’s Secret to 20-Year Relationships

Korea University Guro Hospital’s cancer center emphasizes long-term patient relationships and close multidisciplinary care, with doctors working directly across specialties from diagnosis through treatment, survivorship and hospice care.

Cancer Survivors Generally Have Healthier Diets, but Quality Declines With Age Among Those Diagnosed Young

A study found that cancer survivors generally have healthier diets than the general population, but those diagnosed with cancer at a younger age tend to experience a decline in diet quality as they grow older.

Onconic Therapeutics Begins Phase 3 Trial of Zastaprazan Injection in China, Secures $1 Million Milestone

Onconic Therapeutics said its Chinese licensing partner Livzon Pharmaceutical Group has begun dosing the first patient in a Phase 3 trial of injectable zastaprazan, triggering a $1 million development milestone.

Lunit SCOPE Study in Hard-to-Treat Cancer Published in Nature Medicine

Lunit’s AI biomarker platform SCOPE was used in a study of first-line treatment for HER2-positive advanced biliary tract cancer that has been published in Nature Medicine.

Noeul to Present European Research on AI Blood Analysis for Detecting Abnormal Cells in Leukemia

Noeul will present clinical evidence in Europe for an AI blood analysis technology that can analyze key blood counts and screen for abnormal cells associated with serious blood diseases using just 5 microliters of blood from infants, newborns and children.

Dementia vs. Normal Aging: How to Spot the Differences and Take Action

September 21 is Dementia Overcoming Day, highlighting that dementia affects all age groups due to rapid aging.

Semaglutide and NAION: What Recent Research Reveals About Your Eye Health

Controversy surrounds the rare vision abnormalities linked to semaglutide, the key ingredient in Wegovy and Ozempic.

NeogenLogic Receives U.S. Patent Decision for AI Technology to Identify Cancer Vaccine Targets

SCL Science subsidiary NeogenLogic has received a decision to grant a U.S. patent for technology that uses artificial intelligence to identify cancer targets most likely to trigger an immune response in individual patients.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.